Allergan Finance LLC 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 4, 2010
WATSON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specifi-ed in Its Charter)
311 Bonnie Circle
Corona, California 92880
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (951) 493-5300
(Former name or former address, if changed since last report): Not applicable.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On August 4, 2010, Watson Pharmaceuticals, Inc. (the Company) announced that Thomas R. Russillo would be succeeded by Sigurdur Oli Olafsson as Executive Vice President, Global Generics, effective September 1, 2010. Mr. Russillo will retire from the Company at the end of 2010.
The news release announcing Mr. Russillos retirement and Mr. Olafssons appointment is attached hereto as Exhibit 99.1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.